Dermatology

Increasing diversity in research, from basic science to clinical trials, remains essential for advancing equitable healthcare outcomes.

Achieving comprehensive education in skin of colour (SoC) dermatology remains a challenge in residency programs, with significant disparities in exposure to diverse skin tones across institutions.

Patients with severe alopecia areata (AA) may experience prolonged hair regrowth even after discontinuing treatment with bempikibart, according to findings from the SIGNAL-AA phase 2a study presented at the American Academy of Dermatology (AAD) Annual Meeting.

A phase 2 clinical trial has demonstrated that a once-daily oral tyrosine kinase 2 (TYK2) inhibitor significantly improves symptoms in adults with moderate to severe plaque psoriasis, achieving high clearance rates with a safety profile comparable to placebo.

A new analysis of five clinical trials confirms that dupilumab significantly improves lichenification in patients with moderate to severe atopic dermatitis (AD) across all ages and racial backgrounds.

Artificial intelligence (AI) is becoming a key tool in skin cancer diagnosis, but patient acceptance remains a critical aspect of its implementation.

A recent study has revealed that adult survivors of childhood cancer face a significantly elevated risk of developing melanoma, underscoring the necessity for vigilant long-term monitoring and tailored preventive strategies.

A recent global retrospective cohort study has demonstrated that dupilumab, a monoclonal antibody used to treat atopic dermatitis (AD), offers a favorable cardiometabolic safety profile compared to traditional systemic agents such as methotrexate and cyclosporine.

The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for Zabalafin Hydrogel, a novel therapy designed to treat mild to moderate atopic dermatitis (AD) comprehensively.

Long-term data reveal that bimekizumab, a dual IL-17A and IL-17F inhibitor, provides sustained symptom control for patients with hidradenitis suppurativa (HS).

A recent meta-analysis suggests that statin use is associated with improved survival outcomes in patients with cancer undergoing immune checkpoint inhibitor (ICI) therapy.

A recently published review examined the impact of obesity, diabetes, and smoking on surgical outcomes for patients with hidradenitis suppurativa (HS).

Recent advancements in artificial intelligence (AI) are reshaping dermatology, particularly in diagnosing skin diseases like skin cancer.

Survivors of blood or marrow transplants (BMT) face a significantly higher risk of developing cutaneous malignant neoplasms, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma, according to a recent cohort study.

The University of Pennsylvania Health System has revealed that targeted educational interventions can significantly enhance healthcare workers’ understanding and management of regulated medical waste (RMW) in a recent study.

A new retrospective study has shed light on the incidence of cutaneous pyogenic granulomas (PGs) by age, sex, and anatomical location.

Understanding why some patients with melanoma respond to immunotherapy while others do not has remained a critical challenge for precision medicine.

A recent clinical trial has shown promising results in treating severe, active vitiligo through a combination of oral medication and phototherapy, offering new hope for managing this challenging condition.

Fixed-combination topical therapies show improvements in acne within the first 4 weeks of treatment, according to new data compiled from pivotal clinical trials.

A groundbreaking clinical trial has provided valuable insights into the management of dermatoporosis, a condition characterized by chronic extracellular matrix (ECM) degradation leading to skin atrophy and fragility.

A recent large-scale study published in a dermatology journal provides important insights into the cardiovascular safety of biologic therapies for patients with psoriasis or psoriatic arthritis (PsA).

A new systematic review has shed light on the safety of beta blockers for treating PHACE syndrome, addressing concerns about stroke risk in patients with cerebrovascular and cardiovascular anomalies.

A recent study has highlighted metformin’s potential role in reducing the risk of non-melanoma skin cancers (NMSC), offering intriguing possibilities for dermatological and oncological care.

A new study reveals that patients with cutaneous lupus erythematosus (CLE) face significantly higher risks of atherosclerotic cardiovascular disease (ASCVD) compared to the general population.

A recent study has uncovered promising advancements in the fight against Stage II melanoma by introducing a novel biomarker technique, immune Förster resonance energy transfer (iFRET).

An epidemiological study has shed light on the primary risk factors driving Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer.

Patients with moderate-to-severe atopic dermatitis who did not initially meet response criteria for lebrikizumab at 16 weeks can still achieve improvements with continued therapy, according to a recent clinical trial analysis.

The VISIBLE trial sets a benchmark for diversity in psoriasis research, achieving rapid enrollment and valuable data for patients with skin of color.

The most commonly treated pediatric cosmetic conditions included hypertrophic and traumatic scars, acne, axillary and facial hyperhidrosis.

This study highlights the importance of recognizing physiologic volar melanotic macules in clinical practice, particularly in individuals with skin of color

An international expert panel of 43 dermatologists has established an expert consensus on the off-label use of low-dose oral minoxidil (LDOM) for treating hair loss.

In an effort to improve psoriasis research, the VISIBLE clinical trial has made significant strides in diversity, enrolling participants with skin of color (SoC) at an accelerated rate.

A recent cohort study involving 144,447 participants has found a crucial threshold in melanoma risk for tumors with a Breslow thickness between 0.8 and 1.0 mm.

Survivors of cutaneous melanoma (CM) face a 57% increased risk of developing second primary malignancies (SPMs) compared to the general population, according to groundbreaking research from a recent analysis of SEER database data spanning two decades.

Navigating treatment options for hidradenitis suppurativa (HS) may include consideration of clinic-based deroofing as a more effective and economical choice compared to local excision.

A recent multicenter cohort study reveals that preterm infants are more likely to develop severe forms of infantile hemangiomas (IH), raising concerns about delayed diagnosis and potential scarring risks.

A newly published review sheds light on how the digital revolution is reshaping the field of cosmetic dermatology.

A new study has revealed how the protein Rab7a enhances the activity of TPC2, a cellular channel linked to melanoma, the deadliest form of skin cancer.

A cutting-edge alternative to traditional skin creams offers a promising new approach for treating inflammatory skin diseases.

Results from the Phase III ICONIC-LEAD trial reveal that JNJ-2113 (icotrokinra, Johnson & Johnson, New Jersey), an oral peptide targeting the IL-23 receptor, demonstrated improvements in skin clearance among patients with moderate to severe plaque psoriasis.